Our goal is to reimagine nuclear medicine. We are an innovative medicines company developing a pipeline of targeted radioligand therapies and precision imaging radioligands for oncology.
Advanced Accelerator Applications’s approach involves the combination of therapeutics and imaging diagnostics, which we call our oncology theragnostic platform. The idea is to develop complementary drug pairings targeting the same marker or receptor expressed on the tumor that may be used to both image and treat disease.
Different kinds of radioisotopes are used for precision imaging and targeted therapy, depending on the type of energy they release. Some radioisotopes release gamma rays, such as fluorine-18 (F-18) or gallium-68 (Ga-68), which can be useful in the imaging of disease to help determine its extent and location. Other radioisotopes, such as lutetium-177 (Lu-177) or actinium-225 (Ac-225), release beta particles or alpha particles, which can damage targeted cells with a therapeutic effect. Our pipeline of investigational drugs includes several different radioisotopes.
Investigational Candidates in Clinical Development:
Compound(s) are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established and there is no guarantee that they will become commercially available for the use(s) under investigation.
Disease
Preclinical
Phase I
Phase II
Phase III
Neuroendocrine Tumors
(target SSTR)
(target SSTR)
Phase III
177Lu-DOTATATE (GEP-NET)
Targeted Radioligand Therapy
Phase II
177Lu-DOTATATE (Pediatric GEP-NET)
Targeted Radioligand Therapy
Glioblastoma
(target SSTR)
(target SSTR)
Phase I
177Lu-DOTATATE
Targeted Radioligand Therapy
Lung cancer
(target SSTR)
(target SSTR)
Phase I
177Lu-DOTATATE
Targeted Radioligand Therapy
Prostate cancer (target PSMA)
Phase III
177Lu-PSMA-617*
Targeted Radioligand Therapy
Prostate cancer (target PSMA)
Phase I
255Ac-PSMA-617*
Targeted Radioligand Therapy
Prostate cancer (target PSMA)
Phase I
68Ga-PSMA-R2
Precision Radioligand Imaging
Prostate cancer (target PSMA)
Phase III
18F-CTT1057
Precision Radioligand Imaging
Multiple Solid Tumors (target GRPR)
Phase I
177Lu-NeoB
Targeted Radioligand Therapy
Multiple Solid Tumors (target GRPR)
Phase II
68Ga-NeoB
Precision Radioligand Imaging
Glioblastoma, others (target Integrin alphavbeta3/5)
Preclinical
177Lu-FF58
Targeted Radioligand Therapy
Glioblastoma, others (target Integrin alphavbeta3/5)
Phase I
68Ga-FF58
Precision Radioligand Imaging
192116 4/22